Search results
Results from the WOW.Com Content Network
Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last year. The drugmaker is banking on the treatment to help power growth as ...
Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline , a muscarinic agonist ; and trospium chloride , a muscarinic antagonist . [ 1 ]
How much will Cobenfy cost? According to a Bristol Myers Squibb spokesperson, the wholesale cost for a month's supply will be $1,850. Depending on people's insurance coverage, that cost could be ...
Bristol Myers Squibb will sell the drug combination under the brand name Cobenfy. The pharmaceutical company hasn't said how much it will charge for the medication.
The fixed-dose combination medication xanomeline/trospium chloride (Cobenfy) was approved for medical use in the United States in September 2024. [ 29 ] [ 30 ] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors ...
Xanomeline/trospium, sold under the brand name Cobenfy, is an approved combination drug used in the treatment of schizophrenia. [ 6 ] [ 7 ] Trospium chloride is a peripherally selective non-selective muscarinic antagonist to quell peripheral muscarinic agonist-dependent side effects.
Bristol Myers Squibb (NYSE: BMY) Q3 2024 Earnings Call Oct 31, 2024, 8:00 a.m. ET. ... COBENFY is the first truly novel mechanism approved for adults with schizophrenia in decades, and it ...
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey , [ 2 ] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.